Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Heartstream

This article was originally published in The Gray Sheet

Executive Summary

Heartstream: Expecting net proceeds of $32.8 mil. from an initial public offering of 3 mil. shares, the firm says in a registration statement filed with the Securities and Exchange Commission. UBS Securities, Robertson, Stephens, and Cowen & Company will underwrite the offering, expected to be priced at $12 per share. Heartstream says it anticipates using the net proceeds "to fund product introduction, to build a sales and marketing organization, for continuing research and development, for working capital and other general corporate purposes."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel